1. Home
  2. CHRS vs LSE Comparison

CHRS vs LSE Comparison

Compare CHRS & LSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • LSE
  • Stock Information
  • Founded
  • CHRS 2010
  • LSE 2007
  • Country
  • CHRS United States
  • LSE China
  • Employees
  • CHRS N/A
  • LSE N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • LSE Metal Fabrications
  • Sector
  • CHRS Health Care
  • LSE Industrials
  • Exchange
  • CHRS Nasdaq
  • LSE Nasdaq
  • Market Cap
  • CHRS 84.2M
  • LSE 85.6M
  • IPO Year
  • CHRS 2014
  • LSE 2024
  • Fundamental
  • Price
  • CHRS $0.76
  • LSE $5.44
  • Analyst Decision
  • CHRS Buy
  • LSE
  • Analyst Count
  • CHRS 3
  • LSE 0
  • Target Price
  • CHRS $4.68
  • LSE N/A
  • AVG Volume (30 Days)
  • CHRS 1.3M
  • LSE 1.4M
  • Earning Date
  • CHRS 08-07-2025
  • LSE 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • LSE N/A
  • EPS Growth
  • CHRS N/A
  • LSE N/A
  • EPS
  • CHRS N/A
  • LSE 0.52
  • Revenue
  • CHRS $272,251,000.00
  • LSE $69,073,374.00
  • Revenue This Year
  • CHRS N/A
  • LSE N/A
  • Revenue Next Year
  • CHRS $106.56
  • LSE N/A
  • P/E Ratio
  • CHRS N/A
  • LSE $10.82
  • Revenue Growth
  • CHRS 19.87
  • LSE N/A
  • 52 Week Low
  • CHRS $0.66
  • LSE $3.76
  • 52 Week High
  • CHRS $2.43
  • LSE $14.99
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 46.35
  • LSE N/A
  • Support Level
  • CHRS $0.72
  • LSE N/A
  • Resistance Level
  • CHRS $0.77
  • LSE N/A
  • Average True Range (ATR)
  • CHRS 0.04
  • LSE 0.00
  • MACD
  • CHRS 0.00
  • LSE 0.00
  • Stochastic Oscillator
  • CHRS 38.69
  • LSE 0.00

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

About LSE Leishen Energy Holding Co. Ltd. Ordinary Shares

Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment; oil and gas engineering technical services; new energy production and operation; and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment which supplies various equipments, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.

Share on Social Networks: